FDA warns of rare 'eye stroke' risk from GLP-1 drugs
The Food and Drug Administration (FDA) on Monday required pharmaceutical companies to warn patients and healthcare providers of a potential increased risk of a serious eye condition associated with the use of GLP-1 drugs for weight loss and diabetes. Non-arteritic anterior ischemic optic neuropathy (NAION), often referred to as an "eye stroke,” is a rare condition...
Covered in this story
Call it yourself
No calls on $ASB yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Associated Bancorp →Summary aggregated from The Hill's public RSS feed. The full reporting belongs to The Hill — please read it on their site.